Xenon Reports Q3 2024 Financial Results and Business Update

5 days ago · Third Quarter Financial Results. Cash and cash equivalents and marketable securities were $803.3 million as of September 30, 2024, compared to $930.9 million as of …

CouponFollow Extension

$803
OFF

Xenon Reports Q3 2024 Financial Results And Business Update

1 week from now

5 days ago · Third Quarter Financial Results. Cash and cash equivalents and marketable securities were $803.3 million as of September 30, 2024, compared to $930.9 million as of …

xenon-pharma.com

$803
OFF

Xenon Reports Q3 2024 Financial Results And Business Update

1 week from now

5 days ago · Third Quarter Financial Results. Cash and cash equivalents and marketable securities were $803.3 million as of September 30, 2024, compared to $930.9 million as of …

businessinsider.com

$16
OFF

Xenon Reports Q3 2024 Financial Results And Business Update

1 week from now

5 days ago · General and administrative expenses for the quarter ended September 30, 2024 were $16.7 million, compared to $12.8 million for the same period in 2023. The increase of …

financialpost.com

$850
OFF

Xenon Reports Q2 2024 Financial Results And Business Update

1 week from now

Aug 8, 2024 · Second Quarter Financial Results Cash and cash equivalents and marketable securities were $850.6 million as of June 30, 2024, compared to $930.9 million as of …

morningstar.com

$7
OFF

Movano Health Reports Q3 2024 Financial Results And Provides …

1 week from now

3 days ago · Third Quarter 2024 and Recent Financial Highlights. In Q3 2024, Movano Health shipped 339 Evie Rings. The Company reported an operating loss of $7.4 million in Q3 2024, …

nasdaq.com

$3
OFF

Xenon Reports Q3 2024 Financial Results And Business Update

1 week from now

5 days ago · The increase of $3.9 million was primarily attributable to personnel-related costs due to an increase in employee headcount and higher stock-based compensation expense. Other …

stockhouse.com

€2
OFF

CureVac Announces Financial Results For The Third Quarter And …

1 week from now

5 days ago · Financial Result (Finance Income and Expenses) Net financial result for the three and nine months ended September 30, 2024, amounted to €2.2 million and €8.0 million, or a …

curevac.com

8%
OFF

VEON 3Q24 Trading Update: Another Billion Dollar Revenue …

1 week from now

3 days ago · VEON LTD. Amsterdam and Dubai, 14 November 2024 07:00AM CET. VEON Q3 2024 Highlights. Q3 Total revenue of USD 1,038 million, +9.8% YoY; revenue growth in local …

euronext.com

$1
OFF

Panbela Provides Business Update And Reports Q3 2024 Financial …

1 week from now

3 days ago · Third Quarter ended September 30, 2024 Financial Results. General and administrative expenses were approximately $1.1 million in the quarter, nearly flat compared …

businessinsider.com

$8
OFF

Traws Pharma Provides Business Update And Reports Q3 2024 …

1 week from now

3 days ago · Net loss: The net loss for the three months ended September 30, 2024 was $8.5 million, or $8.81 per basic and diluted common share. This compares with a net loss of $4.7 …

businessinsider.com

FAQs about Xenon Reports Q3 2024 Financial Results and Business Update Coupon?

How did Xenon Pharmaceuticals perform in Q3 2024?

In its latest earnings report, Xenon Pharmaceuticals provided significant updates on its clinical programs and financial performance for the third quarter of 2024. The company continues to make strides in epilepsy and major depressive disorder (MDD) research, notably with its lead molecule, azetukalner, showing promising results. ...

Is xenon a good stock to buy in 2027?

With a strong cash reserve of approximately $803 million, Xenon is well-positioned to fund its operations through 2027, setting the stage for a potentially transformative year in 2025, justifying the Buy rating and a price target of $60. ...

What were the financial results of the company in 2024?

Financial Results: Cash, cash equivalents and short-term investments: As of September 30, 2024, the Company had cash, cash equivalents, and short-term investments of approximately $5.4 million, compared to cash, cash equivalents, and short-term investments of approximately $20.8 million at December 31, 2023. ...

How did affimed perform in the third quarter of 2024?

In the third quarter of 2024, Affimed reported significant progress in its clinical trials and financial performance. The company completed enrollment in the AFM24 combination trial for non-small cell lung cancer, with results set to be discussed in December. ...

What was the net loss in Q1 2024?

Net loss in the quarter was approximately $7.2 million, or $1.48 per diluted share, compared to a net loss of $7.8 million, or $53.74 per diluted share, in the same period last year. Total cash was $142,000 as of September 30, 2024. ...

Will affimed be a part of the ash 2024 Conference?

The company completed enrollment in the AFM24 combination trial for non-small cell lung cancer, with results set to be discussed in December. Additionally, Affimed is preparing to present updates on its AFM13 and AFM28 trials at the ASH 2024 conference, further demonstrating its commitment to advancing cancer therapies. ...